US76152G1004 - Common Stock
REVIVA PHARMACEUTICALS HOLDI
NASDAQ:RVPH (4/26/2024, 7:14:30 PM)
After market: 2.97 -0.02 (-0.67%)2.99
+0.01 (+0.34%)
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 10 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
REVIVA PHARMACEUTICALS HOLDI
19925 Stevens Creek Blvd., Suite 100
Cupertino CALIFORNIA 95014
P: 14085018881
CEO: Laxminarayan Bhat
Employees: 10
Website: https://revivapharma.com/
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reviva Pharmaceuticals (NASDAQ:RVPH) just reported results for the fourth quart...
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have...
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –
Here you can normally see the latest stock twits on RVPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: